InvestSMART

Biotron Limited (ASX:BIT)

ALERT: Price-sensitive ASX Announcement for BIT
Current share price for BIT : $0.002 -0.001 (-20%)+
Announcement
Release
13 Jul 2026 11:24AM
Price at Release
$0.003
Full Release
download
Summary
Biotron Limited announced that the first milestone for the acquisition of Sedarex has been met. The European Medicines Agency (EMA) provided feedback on the regulatory pathway for SedRx, a next-generation general anaesthetic, allowing Biotron to proceed with a clinical and regulatory program aligned with EMA expectations. SedRx combines alfaxalone with a solubilising agent and is positioned as a safer alternative to propofol, showing potential advantages in reducing post-anaesthetic neurocognitive impairment. Despite challenges with the Hybrid Marketing Authorisation Application pathway due to the unavailability of Althesin, Biotron continues its R&D efforts and has issued shares to Sedarex’s vendors as part of the milestone achievement.
Key Points
  • First milestone for Sedarex acquisition met.
  • EMA feedback provides regulatory pathway for SedRx.
  • SedRx combines alfaxalone with a solubilising agent.
  • Clinical trials show SedRx may reduce post-anaesthetic impairment.
  • Challenges with Hybrid Marketing Authorisation Application pathway.
  • Continued R&D efforts for SedRx.
  • Shares issued to Sedarex’s vendors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.